Nuove strategie terapeutiche nel carcinoma polmonare non a piccole cellule metastatico
作者： Maido Castiglioni , Massimiliano Pinelli , Javier Rosada , Massimo Bindi
DOI:
关键词:
摘要: Lung cancer is an elevated mortality disease in spite of conventional therapy. Today it possible to identify some molecules, as the epidermal growth factor receptor, involved earliest molecular alterations cancerogenesis. Here we show inhibitors receptor a therapeutic mean.
recentiprogressi.it参考文章(36)
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
M. H. Cullen, L. J. Billingham, C. M. Woodroffe, A. D. Chetiyawardana, N. H. Gower, R. Joshi, D. R. Ferry, R. M. Rudd, S. G. Spiro, J. E. Cook, C. Trask, E. Bessell, C. K. Connolly, J. Tobias, R. L. Souhami, Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life Journal of Clinical Oncology. ,vol. 17, pp. 3188- 3194 ,(1999) , 10.1200/JCO.1999.17.10.3188
L. Crinò, G. V. Scagliotti, S. Ricci, F. De Marinis, M. Rinaldi, C. Gridelli, A. Ceribelli, R. Bianco, M. Marangolo, F. Di Costanzo, M. Sassi, S. Barni, A. Ravaioli, V. Adamo, L. Portalone, G. Cruciani, A. Masotti, G. Ferrara, F. Gozzelino, M. Tonato, Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project Journal of Clinical Oncology. ,vol. 17, pp. 3522- 3530 ,(1999) , 10.1200/JCO.1999.17.11.3522
Christoph A Ritter, Carlos L Arteaga, The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumors Seminars in Oncology. ,vol. 30, pp. 3- 11 ,(2003) , 10.1053/SONC.2003.50027
Stein Kaasa, Eiliv Lund, Erik Thorud, Reidulv Hatlevoll, Herman Høst, Symptomatic treatment versus combination chemotherapy for patients with extensive non‐small cell lung cancer Cancer. ,vol. 67, pp. 2443- 2447 ,(1991) , 10.1002/1097-0142(19910515)67:10<2443::AID-CNCR2820671008>3.0.CO;2-K
RL Woods, CJ Williams, J Levi, J Page, D Bell, M Byrne, ZL Kerestes, A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. British Journal of Cancer. ,vol. 61, pp. 608- 611 ,(1990) , 10.1038/BJC.1990.135
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Román Pérez-Soler, Abraham Chachoua, Lisa A. Hammond, Eric K. Rowinsky, Mark Huberman, Daniel Karp, James Rigas, Gary M. Clark, Pedro Santabárbara, Philip Bonomi, Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 22, pp. 3238- 3247 ,(2004) , 10.1200/JCO.2004.11.057
Daniel T. Milton, Christopher G. Azzoli, Robert T. Heelan, Ennapadam Venkatraman, Jorge E. Gomez, Mark G. Kris, Lee M. Krug, William Pao, Naiyer A. Rizvi, Megan Dunne, Vincent A. Miller, A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer Cancer. ,vol. 107, pp. 1034- 1041 ,(2006) , 10.1002/CNCR.22088
Ugo Pastorino, Massimo Bellomi, Claudio Landoni, Elvio De Fiori, Patrizia Arnaldi, Maria Picchio, Giuseppe Pelosi, Peter Boyle, Ferruccio Fazio, Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. The Lancet. ,vol. 362, pp. 593- 597 ,(2003) , 10.1016/S0140-6736(03)14188-8